Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies

References

• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatol. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Tang H, Huang Y, Duan W, Li C, Meng X, Dong J. A concise review of current guidelines for the clinical management of hepatocellular carcinoma in Asia. Transl Cancer Res. 2017;6(6):1214–1225.
   Web of Science ®Google Scholar
• Xie D-Y, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463.
   PubMed Web of Science ®Google Scholar
• Zhang T, Merle P, Wang H, et al. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr. 2021;10(2):180–192. doi:10.21037/hbsn-2021-7
   PubMed Web of Science ®Google Scholar
• Gnoni A, Licchetta A, Memeo R, et al. Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies. Medicina. 2019;55(12) 754.
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Benson AB, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines®) hepatobiliary cancers version 2.2021; 2021 [cited May 1, 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed April 13, 2022.
   Google Scholar
• Vogel A, Martinelli E, Vogel A. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801–805. doi:10.1016/j.annonc.2021.02.014
   PubMed Web of Science ®Google Scholar
• Feng Z, Rong P, Wang W. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma. Gut. 2020;69(10):1904–1906. doi:10.1136/gutjnl-2019-320116
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Qin S, Ren Z, Feng Y-H, et al. Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: Phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021;10:296–308. doi:10.1159/000513486
   PubMed Web of Science ®Google Scholar
• Astor L. FDA holds off on approval of pembrolizumab/lenvatinib for frontline unresectable HCC; 2020 [cited November 8, 2020]. Available from: https://www.targetedonc.com/view/fda-denies-approval-of-pembrolizumab-lenvatinib-for-frontline-unresectable-hcc. Accessed April 13, 2022.
   Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211. doi:10.1177/0272989X17725740
   PubMed Web of Science ®Google Scholar
• Vogel A, Rimassa L, Sun H-C, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. Liver Cancer. 2021;10:240–248. doi:10.1159/000515302
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947. doi:10.1016/j.jval.2012.05.004
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ni W. Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes. BMC Med Res Methodol. 2020;20(1):241. doi:10.1186/s12874-020-01124-6
   Web of Science ®Google Scholar
• Petto H, Kadziola Z, Brnabic A, et al. Alternative weighting approaches for anchored matching-adjusted indirect comparisons via a common comparator. Value Health. 2019;22(1):85–91. doi:10.1016/j.jval.2018.06.018
   Web of Science ®Google Scholar
• Cheng AL, Kang Y-K, Lin D-Y, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–4075. doi:10.1200/JCO.2012.45.8372
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Chen LT, Martinelli E, Cheng A-L, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334–351. doi:10.1016/j.annonc.2019.12.001
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi:10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17(4):786–802. doi:10.1177/1536867X1801700402
   PubMed Web of Science ®Google Scholar
• Mitchell M, Muftakhidinov B, Winchen T, van Schaik B, Wilms AK. Engauge digitizer software; 2019 [ cited April 27, 2019]. Available from: http://markummitchell.github.io/engauge-digitizer. Accessed. May 11, 2017.
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691. doi:10.1016/S0895-4356(97)00049-8
   PubMed Web of Science ®Google Scholar
• Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602–603. doi:10.1001/jama.2018.21554
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Safety and efficacy of coformulated pembrolizumab/quavonlimab (MK-1308A) in combination with lenvatinib (E7080/MK-7902) in advanced hepatocellular carcinoma (MK-1308A-004). Available from: https://ClinicalTrials.gov/show/NCT04740307. NLM identifier: NCT04740307. Accessed April 27, 2022.
   Google Scholar